Weight loss and persistence with liraglutide 3.0 mg by obesity class in the real‐world effectiveness study in Canada

OBJECTIVE: Liraglutide 3.0 mg is associated with clinically significant weight loss in clinical trials, but real‐world data are lacking. In this analysis, weight loss and persistence outcomes with liraglutide 3.0 mg were assessed across obesity classes, in a real‐world clinical setting. METHODS: Sec...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Obes Sci Pract
Autors principals: Wharton, Sean, Haase, Christiane L., Kamran, Elham, Liu, Aiden, Mancini, Johanna, Neish, Drew, Pakseresht, Arash, Power, G Sarah, Christensen, Rebecca A. G.
Format: Artigo
Idioma:Inglês
Publicat: John Wiley and Sons Inc. 2020
Matèries:
Short Communications
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7448201/
https://ncbi.nlm.nih.gov/pubmed/32874678
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/osp4.420
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars